Citi Pharma Limited (PSX:CPHL)
Pakistan · Delayed Price · Currency is PKR 73.48
-0.89 (-1.20%)
At close: Jul 30, 2026
Citi Pharma Financials Overview
Financials in millions PKR. Fiscal year is July - June.
Millions PKR. Fiscal year is Jul - Jun.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Revenue Revenue Growth | 13,841 | 13,154 | 12,409 | 12,397 | 9,780 | 5,795 |
Revenue Growth | 6.68% | 6.00% | 0.10% | 26.76% | 68.75% | 64.29% |
Gross Profit Gross Profit Growth | 2,560 | 2,018 | 1,586 | 1,507 | 1,363 | 771.9 |
Operating Income Operating Income Growth | 2,084 | 1,604 | 1,206 | 1,167 | 993.48 | 570.97 |
Net Income Net Income Growth | 1,097 | 892.04 | 833.46 | 657.98 | 653.69 | 351.77 |
Earnings Per Share EPS Growth | 4.80 | 3.90 | 3.65 | 2.88 | 2.88 | 1.88 |
EPS Growth | 31.94% | 6.90% | 26.67% | 0% | 53.04% | 29.90% |
| Fiscal Year | FY 2025 |
|---|---|
| Period Ending | Jun '25 Jun 30, 2025 |
Pakistan Pakistan Growth | 12,799 |
Export Export Growth | 364 |
Total Total Growth | 13,163 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Cash & Investments Cash & Investments Growth | 324.19 | 1,590 | 1,418 | 1,580 | 2,000 | 3,074 |
Total Debt Total Debt Growth | 3,566 | 2,950 | 1,455 | 1,843 | 943.48 | 320.81 |
Net Cash (Debt) Net Cash Growth | -3,242 | -1,360 | -36.55 | -262.2 | 1,056 | 2,754 |
Net Cash Growth | - | - | - | - | -61.65% | - |
Net Cash Per Share Net Cash Per Share Growth | -14.20 | -5.95 | -0.16 | -1.15 | 4.66 | 14.77 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -690.96 | -320.7 | 1,338 | -329 | -322.97 | 224.4 |
Capital Expenditures CapEx Growth | -50.75 | -150.06 | -568.2 | -954.47 | -600.46 | -276.7 |
Free Cash Flow Free Cash Flow Growth | -741.71 | -470.77 | 769.4 | -1,283 | -923.43 | -52.3 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Gross Margin | 18.50% | 15.34% | 12.78% | 12.16% | 13.94% | 13.32% |
Operating Margin | 15.06% | 12.20% | 9.72% | 9.42% | 10.16% | 9.85% |
Pretax Margin | 12.13% | 10.30% | 10.32% | 7.72% | 10.84% | 8.62% |
Profit Margin | 7.92% | 6.78% | 6.72% | 5.31% | 6.68% | 6.07% |
FCF Margin | -5.36% | -3.58% | 6.20% | -10.35% | -9.44% | -0.90% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 31, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Dividend Per Share Dividend Per Share Growth | 3.500 | 3.500 | 3.250 | 2.500 | - | 1.364 |
Dividend Per Share Growth | 7.69% | 7.69% | 30.00% | - | - | - |
Dividend Yield | 4.76% | 4.33% | 12.78% | 14.57% | - | - |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 31, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
PE Ratio | 15.31 | 21.51 | 7.81 | 7.41 | 11.41 | - |
Forward PE | - | 14.23 | 6.55 | 6.34 | - | - |
P/FCF Ratio | - | - | 8.46 | - | - | - |
PS Ratio | 1.21 | 1.46 | 0.53 | 0.39 | 0.76 | - |